BioSpace News Archive

Praxis Medical announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of the EndoCore EBUS-TBNA fine needle biopsy device.

The Mark Foundation for Cancer Research announced the recipients of its 2023 Endeavor Award program, providing a total of $12M across seven institutions to support teams of scientists tackling a range of urgent challenges in the prevention, diagnosis, and treatment of cancer.

Piramal Pharma Limited’s Pharma Solutions business, a leading Contract Development and Manufacturing Organization, formally announced the launch of a world-class high-throughput screening facility that augments the existing in-vitro biology capabilities at its drug discovery services site in Ahmedabad, India.

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

The Alzheimer’s Drug Discovery Foundation will be moderating a session, “Emerging Solutions: Novel Approaches to Treating Alzheimer’s Disease,” at the 2023 Clinical Trials on Alzheimer’s Disease conference, which will be held October 24th through 27th at Boston Park Plaza in Boston, Massachusetts.

Voom™ Medical Devices, Inc. is thrilled to announce the introduction of its one-of-a-kind patented Revcon™ Anchor minimally invasive screw, along with the full commercial launch of the Bunionplasty® procedure.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced that the Company is scheduled to release its third quarter 2023 financial results on Monday, November 6, 2023, after the market closes.

Rhythm Pharmaceuticals, Inc. announced several data presentations showing that setmelanotide therapy resulted in sustained and deepened weight loss in patients with severe obesity caused by rare MC4R pathway diseases during The Obesity Society’s Annual Meeting at ObesityWeek®.

NeuroPace, Inc., a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, announced a series of key enhancements to its RNS System, all designed to streamline care.

Kura Oncology, Inc. (Nasdaq: KURA) today announced results from its registration-directed AIM-HN study of tipifarnib in patients with HRAS mutant head and neck squamous cell carcinoma (HNSCC) whose disease is recurrent or metastatic and has progressed after prior therapy.